In vivo validation and further mechanistic deconvolution of the synthetic lethality suggest that pharmacological inhibition of MDM2 or Bcl2 could be a potential therapeutic strategy for the treatment of CRC with PTEN loss. This evidence concerns the gene MDM2 and colorectal carcinoma.